# Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

> **NCT06672705** · PHASE1 · RECRUITING · sponsor: **Timothy Voorhees** · enrollment: 26 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder
- EBV-Related Post-Transplant Lymphoproliferative Disorder
- Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder
- Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
- Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder
- Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Epcoritamab
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06672705
- **Lead sponsor:** Timothy Voorhees
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672705, "Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06672705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*